Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
6.85    -0.15 (-2.14%)
Bid:
6.70
Ask:
7.00
Spread: 0.30 (4.478%)
Market Cap: £47.16m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
22nd Jun 20187:00 amRNSNotification of Major Interest in Shares
21st Jun 20187:00 amRNSNotification of Major Interest in Shares
20th Jun 20182:00 pmRNSNotification of Major Interest in Shares
20th Jun 201811:05 amRNSSecond Price Monitoring Extn
20th Jun 201811:00 amRNSPrice Monitoring Extension
20th Jun 20187:00 amRNSNotification of Major Interest in Shares
19th Jun 20189:05 amRNSSecond Price Monitoring Extn
19th Jun 20189:00 amRNSPrice Monitoring Extension
18th Jun 20187:00 amRNSPositive Results for Phase IIb FLU-v Field Study
23rd May 201812:30 pmRNSResult of AGM
27th Apr 20182:00 pmRNS2017 Annual Report and Financial Statements
19th Apr 20187:01 amRNSAudited 2017 Preliminary Results
19th Apr 20187:00 amRNSChief Executive Officer Steps Down
10th Apr 20187:00 amRNSStatement regarding share price
6th Apr 20187:00 amRNSNotice of Preliminary Results
5th Apr 201812:00 pmRNSDirectors' Dealings
26th Mar 20187:00 amRNSInitial results from a Phase IIb study of FLU-v
16th Jan 20187:00 amRNSAward of Share Options
9th Jan 20187:00 amRNSDirectors' Dealings
21st Dec 20177:00 amRNSAward of Share Options
14th Dec 20172:00 pmRNSDirector's Dealings
30th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSDirectors' Dealings
21st Sep 20177:00 amRNSHalf-year Report
10th Jul 20177:00 amRNSDirectors' Dealings
20th Jun 20177:00 amRNSBoard Change
24th May 20172:00 pmRNSResult of Annual General Meeting
18th May 20177:00 amRNSAward of Deferred Bonus Share Options
28th Apr 20172:00 pmRNS2016 Annual Report and Financial Statements
20th Apr 20177:00 amRNSAudited 2016 Preliminary Results
13th Apr 20177:00 amRNSTrading Update
5th Apr 20177:00 amRNSDirectors' Dealings
21st Feb 20174:30 pmRNSInitiation of a Phase I clinical trial with AGS-v
9th Feb 20177:00 amRNSData from PrEP Biopharm's Ph. IIa clinical studies
5th Jan 20177:00 amRNSDirectors' Dealings
30th Dec 20167:00 amRNSChange of auditor
27th Oct 20167:00 amRNSNotification of Major Interest in Shares
12th Oct 20167:00 amRNSDirectors' Dealings
23rd Sep 20167:00 amRNSExercise of Share Options
22nd Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSTrading Update
8th Sep 20167:00 amRNSNotification of Major Interest in Shares
2nd Sep 20167:00 amRNShVIVO Landmark Asthma Study Underway
4th Aug 20167:00 amRNSDirectors' Dealings
12th Jul 201612:45 pmRNSNotification of Major Interest in Shares
14th Jun 201612:00 pmRNSFavourable results for PrEP Biopharm's Flu Study
24th May 20167:00 amRNSDavid Norwood Lock-in Deed
23rd May 201612:00 pmRNSResult of AGM
28th Apr 20162:05 pmRNS2015 Annual Report and Financial Statements
27th Apr 20167:00 amRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.